Publications

Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin

Algaze SD, Park W, Harrington TJ, Mudad R

Biomarker-based therapy in pancreatic ductal adenocarcinoma: an emerging reality?

BA Krantz, EM O'Reilly

Brain metastases in pancreatic ductal adenocarcinoma: Assessment of molecular genotype–phenotype features—an entity with an increasing incidence?

EJ Jordan, MA Lowery, O Basturk, PJ Allen, KH Yu, V Tabar, K Beal, ...

Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).

RK Das, L Furchtgott, JA Meyerhardt, AB Nixon, F Innocenti, D Cunha, ...

Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)

RK Das, L Furchtgott, FS Ou, D Swanson, B Hayete, B Harms, D Cunha, ...

Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma

Yu KH, Ricigliano M, McCarthy B, Chou JF, Capanu M, Cooper B, Bartlett A, Covington C, et al.

Classification of pancreatic Cancer: ready for practical application?

DN Khalil, EM O'Reilly

Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection

Husnain M, Park W, Ramos JC, Johnson TE, Chan J, Dasari A, Mudad R, Hosein PJ

Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention

MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, M Capanu, ...

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease

E Ter Veer, LB van Rijssen, MG Besselink, RMA Mali, JD Berlin, S Boeck, ...

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Aguiar PN Jr, Haaland B, Park W, San Tan P, Del Giglio A, …

Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small …

L Mezquita, K Arbour, E Auclin, D Saravia, H Rizvi, L Hendriks, ...

Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab

Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, et al.

Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations

ZI Hu, J Shia, ZK Stadler, AM Varghese, M Capanu, E Salo-Mullen, ...

Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma

JJ Harding, G Abu-Zeinah, JF Chou, DH Owen, M Ly, MA Lowery, ...

High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid …

V Florou, W Park, AE Torres, S Algaze, D Saravia, BA Wilky, JR Merchan, ...

HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer …

EM O'Reilly, EH Borazanci, KH Yu, AM Varghese, H Estrella, D Kamins, ...

Incidence, management, and implications of visceral thrombosis in pancreatic ductal adenocarcinoma

A Mier-Hicks, M Raj, RK Do, KH Yu, MA Lowery, A Varghese, EM O'Reilly

MA19. 04 The Clinical Implication of Frameshift Indel Mutation Burden in Non-Small Cell Lung Cancer (NSCLC)

YK Chae, W Park, D Saravia, V Florou, S Chang, S Wang, L Chiec, ...

Massive enoxaparin overdose partially reversed with low doses of protamine

J de Olano, F Balogun, C Waslsh, C Ramprasad, D Green, M Miller, ...

Metastatic pancreatic cancer: ASCO clinical practice guideline update

DPS Sohal, EB Kennedy, A Khorana, MS Copur, CH Crane, ...

MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.

DY Oh, SE Al-Batran, HC Chung, A Hollebecque, S Iqbal, KP Kim, J Lacy, ...

MORPHEUS: A phase ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with gastric or pancreatic cancer

DY Oh, SE Al-Batran, HC Chung, A Hollebecque, S Iqbal, KP Kim, J Lacy, ...

Nano-liposomal irinotecan and 5-FU/LV (N+ F) for the treatment of advanced PDAC: Memorial Sloan Kettering (MSK) Single Cancer Center Evaluation.

DC Glassman, AM Desai, GY Ku, J Li, JJ Harding, AM Varghese, ...

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

DC Glassman, RL Palmaira, CM Covington, AM Desai, GY Ku, J Li, ...

Neutrophil-lymphocyte-ratio to complement the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 …

D Saravia, N Okabe, W Park, D Kwon, L Mezquita, YK Chae, R Mudad, ...

P1. 01-68 Correlation of the lung immune prognostic index (LIPI) and PDL1 status with outcomes for immune checkpoint inhibitors in advanced NSCLC patients

L Mezquita, W Park, K Arbour, E Auclin, L Hendriks, D Planchard, ...

P1. 04-19 Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict survival after immunotherapy in non-small cell lung cancer

M Oh, D Saravia, S Agte, A Rahbari, W Park, G Lopes, Y Chae

P2. 01-82 Neutrophil-to-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors

D Saravia, S Agte, N Okabe, W Park, D Kwon, R Mudad, H Suzuki, ...

Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior

Sahin IH, Elias H, Chou JF, Capanu M, O'Reilly EM

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, et al.

Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S).

IH El Dika, M Capanu, JF Chou, JJ Harding, AD Hrabovsky, RKG Do, ...

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma

MA Lowery, DP Kelsen, M Capanu, SC Smith, JW Lee, ZK Stadler, ...

Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.

KH Yu, S Mantha, C Tjan, ES Kaufmann, R Brenner, MA Lowery, GY Ku, ...

Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).

BA Krantz, D Tsui, MA Lowery, M Capanu, KH Yu, DP Kelsen, ...

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance)(C8).

GK Abou-Alfa, Q Shi, JJ Knox, A Kaubisch, J Posey, BR Tan, P Kavan, ...

Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the iSEND model.

W Park, L Mezquita, N Okabe, D Kwon, D Saravia, YK Chae, A Desai, ...

Preface for special edition pancreas cancer

EM O’Reilly, L Zheng

Prospective analysis of somatic and germline genetic alterations in patients with ampullary carcinomas.

W Wong, EM O'Reilly, AM Varghese, KH Yu, CA Iacobuzio-Donahue, ...

Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms

MA Lowery, W Wong, EJ Jordan, JW Lee, Y Kemel, J Vijai, D Mandelker, ...

Qualitative study of cancer patients’ advance care planning (ACP) values.

R Agarwal, AE Volandes, DR Romano, M Genoff, EM O'Reilly, W Breitbart, ...

Rivaroxaban thromboprophylaxis in high-risk ambulatory cancer patients receiving systemic therapy: results of a randomized clinical trial (CASSINI)

AA Khorana, GA Soff, AK Kakkar, S Vadhan-Raj, H Riess, T Wun, ...

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, et al.

Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.

KA Goodman, N Hall, TS Bekaii-Saab, FS Ou, E Twohy, MO Meyers, ...

The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review

Farhat F, Torres A, Park W, de Lima Lopes G, Mudad R, Ikpeazu C, Abi Aad S

Understanding pancreatic diseases using animated pancreas patient: informing patients for better health outcomes with visual formats of learning

S Munigala, TB Gardner, EM O'Reilly, C Fernandez-del Castillo, AH Ko, ...

Variability of pelvic MRI performance in a prospective multicenter rectal cancer trial NCCTG N1048 (Alliance).

MJ Gollub, Q Shi, S Nougaret, P Subramanian, J Zhang, MV Knopp, ...

Visceral thromboses in pancreas adenocarcinoma: systematic review

AM Hicks, A DeRosa, M Raj, R Do, KH Yu, MA Lowery, A Varghese, ...

Visceral Thrombosis in Pancreas Ductal Adenocarcinoma: Incidence, Management and Implications

AM Hicks, M Raj, RK Do, KH Yu, MA Lowery, A Varghese, EM O’Reilly

A novel scoring system to predict survival in patients with advanced pancreatic adenocarcinoma: The Memorial Sloan Kettering Cancer Center (MSKCC) Prognostic Score (MPS).

AC Yang, A Wiesenthal, AS Epstein, J Goldberg, J Meadows, EM O'Reilly, ...